Gestational diabetes mellitus, adiposity and early adipose tissue development: A role for epigenetic modulations?

Gestational diabetes mellitus, adiposity and early adipose tissue development: A role for epigenetic modulations? - GESA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004370

Enrollment

Registered

2012-09-24

Start date

2010-02-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

O24.4 E66.9 P08.0

Interventions

Group 1: control group, lean, healthy pregnant women with 18.5 kg/m2 30 kg/m2 before pregnancy, no gestational diabetes (GDM) Group 3: Obese pregnat women with BMI > 30 kg/m2 before pregnancy, Gestati

Eligibility

Sex/Gender

Female

Age

18 Years to 43 Years

Inclusion criteria

Inclusion criteria: -gestational age < 32th week of gestation -18.5 < BMI < 40 -age: minimun 18 years and maximun 43 years -written informed consent -sufficient German language skills

Exclusion criteria

Exclusion criteria: - risk pregnancies (multiparae, rhesus incompatibility, hepatitis B infection, HELLP syndrome, pre-eclampsia, more than 4 deliveries ) - hypertension - pregravid diabetes Type 1 or Type 2 - gastrointestinal disorders accompanied by maldigestion, malabsorption, or elevated energy and nutritional requirements (eg, gluten enteropathy) - known metabolic defects (eg, phenylketonuria) - psychiatric diseases - drug or alcohol abuse.

Design outcomes

Primary

Measure	Time frame
Offspring adipose tissue development at 1 year postpartum. Measurements are determined by 1.) skin fold thickness (caliper) and 2.) with ultrasound imaging	—

Secondary

Measure	Time frame
- maternal and fetal inflammatory status measuring inflammatory markers e.g. TNF-alpha, IL-6, IL-2, INF-gamma, CRP and Adiponektin in maternal and umbilical cord plasma - plasma lipid profiles (triglycerides, total cholesterin, HDL and LDL cholesterol), glucose and insulin concentration, HOMA-Index at recruitment (33.-36.week of gestation), at delivery and 6 weeks postpartal - Analysis of epigenetic modificationens (histone acetylation, DNA-methylation, miRNA-expression) determined in placenta und in peripheral mononuclear Zellen (PBMC) in cord blood as well as in maternal and fetal plasma samples - weight, lenght, head circumference and arm circumference, as well as measurement of skin fold thickness and ultrasound imaging for determination subcutaneous und preperitoneal adipose tissue at time points 1 week, 6 week, 4 month as well as 12 month postpartal.	—

Measure

Time frame

- maternal and fetal inflammatory status measuring inflammatory markers e.g. TNF-alpha, IL-6, IL-2, INF-gamma, CRP and Adiponektin in maternal and umbilical cord plasma - plasma lipid profiles (triglycerides, total cholesterin, HDL and LDL cholesterol), glucose and insulin concentration, HOMA-Index at recruitment (33.-36.week of gestation), at delivery and 6 weeks postpartal - Analysis of epigenetic modificationens (histone acetylation, DNA-methylation, miRNA-expression) determined in placenta und in peripheral mononuclear Zellen (PBMC) in cord blood as well as in maternal and fetal plasma samples - weight, lenght, head circumference and arm circumference, as well as measurement of skin fold thickness and ultrasound imaging for determination subcutaneous und preperitoneal adipose tissue at time points 1 week, 6 week, 4 month as well as 12 month postpartal.

—

Countries

Germany

Contacts

Public ContactKirsten Uebel

ZIEL- Zentralinstitut für Ernährungs- und Lebensmittelforschung, Else Kröner-Fresenius-Zentrum für Ernährungsmedizin, Lehrstuhl für Ernährungsmedizin

Kirsten.Uebel@wzw.tum.de08161712348

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 20, 2026